GRHL2

Across TCGA pan-cancer cohorts, GRHL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRHL2 data layer compared with 15 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GRHL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GRHL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and COAD are the cancer types where GRHL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	1.000	0.841	.007	35	view →
LUAD	OS	Tertile	III,IV	0.815	0.273	.001	13	view →
COAD	DFS	Median	All	0.928	1.000	.030	12	view →
HNSC	OS	Quartile	All	0.782	0.934	.008	11	view →
PDAC	DFS	Median	II,III,IV	0.629	0.852	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GRHL2–LSCC (DFS)

Open the LSCC breakdown →